BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 35879775)

  • 1. LncRNA RP3-525N10.2-NFKB1-PROS1 triplet-mediated low PROS1 expression is an onco-immunological biomarker in low-grade gliomas: a pan-cancer analysis with experimental verification.
    Zhou Y; Xiao D; Jiang X
    J Transl Med; 2022 Jul; 20(1):335. PubMed ID: 35879775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PROS1 shapes the immune-suppressive tumor microenvironment and predicts poor prognosis in glioma.
    Wang J; Wu N; Feng X; Liang Y; Huang M; Li W; Hou L; Yin C
    Front Immunol; 2022; 13():1052692. PubMed ID: 36685506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autophagy-related CMTM6 promotes glioblastoma progression by activating Wnt/β-catenin pathway and acts as an onco-immunological biomarker.
    Dai L; Xiao J; Li X; Tao Y; Zhou P; Lyu L; Shi Z; Liang X; Jia Z; Jiang S
    J Gene Med; 2024 May; 26(5):e3685. PubMed ID: 38686653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia-Related lncRNA Correlates With Prognosis and Immune Microenvironment in Lower-Grade Glioma.
    Xu S; Tang L; Liu Z; Luo C; Cheng Q
    Front Immunol; 2021; 12():731048. PubMed ID: 34659218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
    Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
    Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and validation of an individualized prognostic signature of lower-grade glioma based on nine immune related long non-coding RNA.
    Maimaiti A; Jiang L; Wang X; Shi X; Pei Y; Hao Y; Paerhati H; Zibibula Y; Abudujielili A; Kasimu M
    Clin Neurol Neurosurg; 2021 Feb; 201():106464. PubMed ID: 33454543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA methylation-regulated YTHDF2 correlates with cell migration and immune cell infiltration in glioma.
    Jiang X; Chen X; Huang X; Wang C; Wang C; Pan C; Cho WC; Nie Z; Pu J; Wang W
    Aging (Albany NY); 2022 Jun; 14(19):7774-7793. PubMed ID: 35661004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cullin-7 (CUL7) is overexpressed in glioma cells and promotes tumorigenesis via NF-κB activation.
    Xu J; Zhang Z; Qian M; Wang S; Qiu W; Chen Z; Sun Z; Xiong Y; Wang C; Sun X; Zhao R; Xue H; Li G
    J Exp Clin Cancer Res; 2020 Apr; 39(1):59. PubMed ID: 32252802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Value of Immune-Related lncRNA SBF2-AS1 in Diffuse Lower-Grade Glioma.
    Zhang Q; Liu XJ; Li Y; Ying XW; Chen L
    Technol Cancer Res Treat; 2021; 20():15330338211011966. PubMed ID: 34159865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LncRNA NDUFA6-DT: A Comprehensive Analysis of a Potential LncRNA Biomarker and Its Regulatory Mechanisms in Gliomas.
    Huang R; Kong Y; Luo Z; Li Q
    Genes (Basel); 2024 Apr; 15(4):. PubMed ID: 38674418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pan-cancer integrated bioinformatics analysis reveals cuproptosis related gene FDX1 is a potential prognostic and immunotherapeutic biomarker for lower-grade gliomas.
    Huang W; Wu Y; Zhu J; Luo N; Wang C; Liu S; Cheng Z
    Front Mol Biosci; 2023; 10():963639. PubMed ID: 36825202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Next-generation sequencing identifies HOXA6 as a novel oncogenic gene in low grade glioma.
    Xiulin J; Wang C; Guo J; Wang C; Pan C; Nie Z
    Aging (Albany NY); 2022 Mar; 14(6):2819-2854. PubMed ID: 35349479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long non coding RNA SLC26A4-AS1 exerts antiangiogenic effects in human glioma by upregulating NPTX1 via NFKB1 transcriptional factor.
    Li H; Yan R; Chen W; Ding X; Liu J; Chen G; Zhao Q; Tang Y; Lv S; Liu S; Yu Y
    FEBS J; 2021 Jan; 288(1):212-228. PubMed ID: 32255252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenic cell death-related risk signature predicts prognosis and characterizes the tumour microenvironment in lower-grade glioma.
    Cai J; Hu Y; Ye Z; Ye L; Gao L; Wang Y; Sun Q; Tong S; Yang J; Chen Q
    Front Immunol; 2022; 13():1011757. PubMed ID: 36325335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas.
    Zhao WJ; Ou GY; Lin WW
    Front Immunol; 2021; 12():682415. PubMed ID: 34054873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNMT3A promotes glioma growth and malignancy via TNF-α/NF-κB signaling pathway.
    Su X; Liu J; Tu Z; Ji Q; Li J; Liu F
    Transl Cancer Res; 2024 Apr; 13(4):1786-1806. PubMed ID: 38737693
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Ge X; Xu M; Cheng T; Hu N; Sun P; Lu B; Wang Z; Li J
    Front Immunol; 2022; 13():974346. PubMed ID: 36275718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RFC2: a prognosis biomarker correlated with the immune signature in diffuse lower-grade gliomas.
    Zhao X; Wang Y; Li J; Qu F; Fu X; Liu S; Wang X; Xie Y; Zhang X
    Sci Rep; 2022 Feb; 12(1):3122. PubMed ID: 35210438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic biomarker SGSM1 and its correlation with immune infiltration in gliomas.
    Li J; Wang J; Ding Y; Zhao J; Wang W
    BMC Cancer; 2022 Apr; 22(1):466. PubMed ID: 35484511
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Gao X; Liu Y; Hong S; Yang H; Guan B; Ma X
    J Integr Neurosci; 2023 Aug; 22(5):135. PubMed ID: 37735118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.